Published Date: 27 Apr 2023
In the second week of life, 83 percent of newborns who were fed formula milk had Clostridium difficile and Clostridium perfringens, but by the end of the third week, all infants had these infections.
Read Full NewsAn investigative inhaled formulation of the psychedelic mebufotenin is linked to significant improvements in depression symptoms compared to placebo, a phase 2b trial shows.
A biological computer using human neurons learns Doom within 1 week, highlighting rapid adaptive learning and potential advantages over traditional AI systems.
The findings could fill a treatment gap for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who also carry TP53 mutations.
Both drugs increase overall and progression-free survival.
1.
Adjuvant ICIs: A Winner and a Loser in Clear Cell Renal Cell Carcinoma?
2.
The risk of ovarian cancer is not increased by salpingectomy, according to JAMA.
3.
Investigating the Relationship Between GERD and Anxiety/Depression.
4.
Chronic stress and obesity work together to accelerate pancreatic cancer development and growth, study finds
5.
FDA Leaders Explain Their Choice Regarding Cancer Risk Warning in CAR-T Investigation.
1.
Understanding Axitinib: What You Need To Know For Your Treatment Plan
2.
All You Need To Know About Partial Thromboplastin Time (PTT) Test
3.
Unveiling Canine Blood Clots Over Time: A Look at Low-Field MRI's Diagnostic Potential
4.
Screening Strategies in Oncology: A Subspecialty Guide to Early Detection and Better Outcomes
5.
Polyposis Syndrome: Causes, Symptoms, and Treatment Options
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V
3.
Navigating the Complexities of Ph Negative ALL - Part XI
4.
Updates on the First Line Management of ALK+ NSCLC
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation